Uveitis Treatment Market
Uveitis Treatment Market Study by Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungals, and Analgesics from 2024 to 2034
Analysis of Uveitis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Uveitis Treatment Market Outlook (2024 to 2034)
As per a new study published by Fact.MR, the global uveitis treatment market size is estimated at US$ 791 million in 2024 and is projected to expand at a CAGR of 5.8% to reach US$ 1.4 billion by 2034-end.
Increasing prevalence of uveitis in certain countries is attributed to a growing aging population, rising incidence of autoimmune diseases, and improved diagnostic capabilities. As uveitis incidence climbs, demand for effective treatment intensifies.
Uveitis treatment aims to alleviate symptoms and prevent vision loss by managing inflammation in the uvea, the eye's central layer. Common treatment modalities include corticosteroids to reduce inflammation, immunosuppressive medications for severe or persistent cases, and biologics targeting specific immune pathways.
In some instances, surgical interventions like vitrectomy or the implantation of medication delivery devices become necessary. Treatment objectives focus on inflammation reduction, complication prevention, and vision preservation, contingent upon the underlying cause, severity, and type of uveitis.
Key Market Growth Drivers
- Innovative therapeutic approaches are being developed as a result of significant progress in understanding the etiology of uveitis.
- Expansion of the uveitis treatment market size is fueled by the introduction of sustained-release medication delivery technologies, including biodegradable microspheres and intravitreal implants.
- These technologies ensure prolonged drug exposure, enhancing patient compliance by reducing the necessity for systemic drugs or injections.
- Significant advancements in understanding the pathophysiology of uveitis are fostering the development of novel treatment modalities. Biologic therapies, such as fusion proteins and monoclonal antibodies targeting specific cytokines or cell surface markers, offer opportunities for more effective and personalized therapeutic interventions.
- Increased funding from pharmaceutical companies and organizations for research and development initiatives aimed at uveitis treatment is driving the exploration of new medicinal agents and treatment strategies.
- Expansion of the market is further fueled by the proliferation of open-angle glaucoma treatments available through retail pharmacies and the growing presence of such pharmacies in various countries.
| Report Attribute | Detail |
|---|---|
| Uveitis Treatment Market Size (2024E) | US$ 791 Million |
| Forecasted Market Value (2034F) | US$ 1.4 Billion |
| Global Market Growth Rate (2024 to 2034) | 5.8% CAGR |
| North America Market Share (2024E) | 36.8% |
| East Asia Market Value (2024E) | US$ 117 Million |
| Corticosteroids Segment Value (2034F) | US$ 319.9 Million |
| Anterior Uveitis Segment Value (2034F) | US$ 830 Million |
| Infectious Uveitis Segment Value (2034F) | US$ 1.21 Billion |
| Key Companies Profiled | Sun Pharmaceutical Industries Ltd.; EyePoint Pharmaceuticals, Inc.; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Inflammasome Therapeutics Inc.; Graybug Vision, Inc.; TopiVert Pharma Ltd.; Pfizer Inc.; Bausch Health Companies Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Contributing to Increasing Demand for Uveitis Treatment?
“Advancements in Sustained-Release Drug-Delivery Techniques Lowering Risk of Adverse Effects”
One of the key uveitis treatment market trends is technological advancements in therapeutic techniques, particularly in the development of drug-delivery devices with sustained release. Due to their ability to deliver sustained medication exposure directly to the afflicted eye tissues, these systems incorporating biodegradable microspheres and intravitreal implants offer considerable benefits. Their reduction in the requirement for frequent injections or systemic drugs not only improves patient compliance and convenience but also lowers the possibility of adverse systemic effects.
What Issue is Primarily Hindering Adoption of Uveitis Treatment?
“Rising Concerns Over Immune Suppression and Susceptibility to Infection”
By focusing on certain inflammatory pathways, biological treatments are transforming the management of uveitis but not without risk. Uveitis treatments may suppress the immune system, increasing the susceptibility to infections, especially in individuals with compromised immune systems or underlying medical conditions.
Healthcare providers must meticulously assess the risk-benefit balance of biologics, considering the patient's overall health, severity of their uveitis, and potential side effects. Professionals prioritize the safe and effective management of uveitis by meticulously evaluating these factors and optimizing treatment choices to maximize therapeutic outcomes. However, rising concerns over associated risks are constraining market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America is estimated to hold 36.8% revenue share of the global market in 2024. Demand for uveitis treatment in East Asia is projected to rise at 7% CAGR from 2024 to 2034.
What Has Made the United States a Lucrative Market for Uveitis Treatment Providers?
“Targeted Approaches to Modulate Specific Inflammatory Pathways Associated with Uveitis”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 214 Million |
| Growth Rate (2024 to 2034) | 5% CAGR |
| Projected Value (2034F) | US$ 347 Million |
In the United States, the therapeutic options for uveitis are significantly expanding with the introduction of potent medications like biologic therapy and sustained-release drug delivery methods. Biologic treatments, such as fusion proteins and monoclonal antibodies, offer targeted approaches to modulate specific inflammatory pathways associated with uveitis. Compared to conventional immunosuppressive drugs, these treatments enhance patients' outcomes and quality of life by providing a more precise and effective therapeutic alternative.
Why is Demand for Uveitis Treatment Increasing Steadily in Japan?
“Extensive Availability of Specialized Eye Care Facilities”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 39 Million |
| Growth Rate (2024 to 2034) | 5.8% CAGR |
| Projected Value (2034F) | US$ 70 Million |
Strong healthcare sector in Japan is essential to meeting the rising need for uveitis treatment. People with uveitis have easy access to diagnostic and treatment choices due to the extensive availability of medical services, including specialized eye care facilities. Better patient outcomes result from the swift detection and management of uveitis, which is made possible by increasing access to healthcare resources.
Availability of specialist eye care centers furnished with advanced diagnostic and therapeutic modalities is enabling medical professionals to offer patients with uveitis thorough and efficient care in Japan. All of these factors are contributing to uveitis market growth in the country.
Category-wise Insights
Based on disease, the market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is poised to hold 57.8% market share in 2024. The significant number of cases of anterior uveitis worldwide is due to its multifactorial nature, which includes autoimmune illnesses, infections, and ocular traumas. The necessity for uveitis therapy is increasing in this segment since untreated cases result in blindness, cataracts, and glaucoma.
Which Treatment Modality is Widely Preferred by Healthcare Providers?
“Greater Effectiveness of Corticosteroids in Reducing Eye Inflammation Than Other Drugs”
| Attribute | Corticosteroids |
|---|---|
| Segment Value (2024E) | US$ 172.5 Million |
| Growth Rate (2024 to 2034) | 6.4% CAGR |
| Projected Value (2034F) | US$ 319.9 Million |
By treatment type, the corticosteroids segment is set to hold 21.8% of the uveitis treatment market share in 2024 and is further projected to account for a 22.9% market share by the end of 2034. Rising demand for corticosteroids is driven by their greater effectiveness in reducing eye inflammation as compared to other drugs.
Patients with uveitis benefit from consumption of corticosteroids because they assist in reducing the immunological response that causes inflammation. Beyond this, corticosteroids are an adaptable therapeutic choice for uveitis since they are given as injections, ocular drops, or oral drugs.
Which Distribution Channel Accounts for Substantial Revenue Generation?
“Hospital Pharmacies Generating High Revenue Due to Large Patient Base”
| Attribute | Hospital Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 361.9 Million |
| Growth Rate (2024 to 2034) | 5.7% CAGR |
| Projected Value (2034F) | US$ 632.2 Million |
Hospital pharmacies occupy a significant share of the market. Uveitis requires ongoing care, leading to a large patient base in hospitals and a consistent demand for uveitis drugs seen by hospital pharmacists. With a growing number of uveitis patients requiring continuous access to prescribed medications, hospitals generate increased revenue from treating this condition. Moreover, hospital pharmacies leverage agreements with specific providers of uveitis medicines, enabling them to procure these drugs at reasonable costs and enhance their earnings from sales.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the uveitis treatment market are using effective pricing strategies. Companies need to take into account several variables such as manufacturing costs, market demand, rival pricing, and reimbursement procedures. Sustaining corporate development and maintaining market share necessitates finding a balance between profitability and competitive pricing.
- In January 2024, Tarsier Pharma obtained approval from the United States FDA under the Special Protocol Assessment (SPA) for the Tarsier-04 Phase 3 trial of the TRS01 ophthalmic solution, targeting non-infectious uveitis, including uveitic glaucoma.
- In October 2021, the FDA greenlit XIPER, or triamcinolone acetonide injectable suspension, for suprachoroidal use, addressing macular edema linked with uveitis.
- In December 2020, Alimera Sciences Europe Ltd. introduced ILUVIEN in the Netherlands, targeting diabetic macular edema (DME) and non-infectious posterior segment uveitis (NIPU), aiming for geographic expansion to reach more physicians and patients.
Fact.MR provides detailed information about the price points of prominent players in the uveitis treatment market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Segmentation of Uveitis Treatment Market Research
-
By Treatment :
- Corticosteroids
- Immunosuppressants
- Monoclonal Antibodies
- Cycloplegic Agents
- Antibiotics
- Antivirals
- Antifungals
- Analgesics
-
By Disease :
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
-
By Cause :
- Infectious Uveitis
- Non-infectious Uveitis
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Treatment
- 6.2. Disease
- 6.3. Cause
- 6.4. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Treatment
- 7.1. Corticosteroids
- 7.2. Immunosuppressants
- 7.3. Monoclonal Antibodies
- 7.4. Cycloplegic Agents
- 7.5. Antibiotics
- 7.6. Antivirals
- 7.7. Antifungals
- 7.8. Analgesics
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Disease
- 8.1. Anterior Uveitis
- 8.2. Posterior Uveitis
- 8.3. Intermediate Uveitis
- 8.4. Panuveitis
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cause
- 9.1. Infectious Uveitis
- 9.2. Non-infectious Uveitis
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 10.1. Hospital Pharmacies
- 10.2. Retail Pharmacies
- 10.3. Online Pharmacies
- 10.4. Drug Stores
- 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. Middle East & Africa
- 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 19. Sales Forecast 2024 to 2034 by Treatment, Disease, Cause, Distribution Channel, and Region for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Sun Pharmaceutical Industries Ltd.
- 21.2. EyePoint Pharmaceuticals, Inc.
- 21.3. Ophthotech Corporation
- 21.4. Regeneron Pharmaceuticals, Inc.
- 21.5. Takeda Pharmaceutical Company Limited
- 21.6. Inflammasome Therapeutics Inc.
- 21.7. Graybug Vision, Inc.
- 21.8. TopiVert Pharma Ltd.
- 21.9. Pfizer Inc.
- 21.10. Bausch Health Companies Inc.
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 25: North America Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 26: North America Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 28: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 37: Latin America Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 38: Latin America Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 40: Latin America Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 41: Latin America Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 43: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 44: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: Western Europe Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 50: Western Europe Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 51: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 52: Western Europe Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 53: Western Europe Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 54: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 55: Western Europe Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 56: Western Europe Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 58: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 65: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 66: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 67: Eastern Europe Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 68: Eastern Europe Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 69: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 70: Eastern Europe Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 71: Eastern Europe Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 72: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 76: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 77: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 78: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 79: East Asia Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 80: East Asia Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 81: East Asia Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 82: East Asia Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 83: East Asia Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 84: East Asia Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 85: East Asia Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 86: East Asia Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 87: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 88: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 89: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 90: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 91: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 92: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 93: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 94: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 95: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 96: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 97: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 98: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 99: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 100: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 101: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 102: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 103: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 104: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 105: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 106: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 107: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 108: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 109: MEA Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023
Table 110: MEA Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034
Table 111: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034
Table 112: MEA Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023
Table 113: MEA Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034
Table 114: MEA Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034
Table 115: MEA Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023
Table 116: MEA Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034
Table 117: MEA Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034
Table 118: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 119: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 120: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 17: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 18: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 20: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 21: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 22: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 23: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 24: North America Market Share Analysis by Country, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 33: North America Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 34: North America Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 36: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 37: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 39: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 40: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 41: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 42: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 43: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 49: Latin America Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 50: Latin America Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 52: Latin America Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 53: Latin America Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 55: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 56: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 57: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 58: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 59: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 60: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 61: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 62: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Western Europe Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 66: Western Europe Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 67: Western Europe Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 68: Western Europe Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 69: Western Europe Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 70: Western Europe Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 71: Western Europe Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 72: Western Europe Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 73: Western Europe Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 74: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 75: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 77: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 78: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 79: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 80: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 81: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 82: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 83: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 84: Eastern Europe Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 85: Eastern Europe Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 86: Eastern Europe Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 87: Eastern Europe Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 88: Eastern Europe Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 89: Eastern Europe Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 90: Eastern Europe Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 91: Eastern Europe Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 92: Eastern Europe Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 93: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 94: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 95: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 96: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 97: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 98: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 99: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 100: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 101: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 102: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 103: East Asia Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 104: East Asia Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 105: East Asia Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 106: East Asia Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 107: East Asia Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 108: East Asia Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 109: East Asia Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 110: East Asia Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 111: East Asia Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 112: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 113: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 115: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 116: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 117: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 118: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 119: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 120: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 121: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 122: South Asia & Pacific Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 123: South Asia & Pacific Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 124: South Asia & Pacific Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 125: South Asia & Pacific Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 126: South Asia & Pacific Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 127: South Asia & Pacific Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 128: South Asia & Pacific Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 129: South Asia & Pacific Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 130: South Asia & Pacific Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 131: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 132: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 133: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 134: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 135: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 136: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 137: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 138: MEA Market Share Analysis by Country, 2024 & 2034
Figure 139: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 140: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 141: MEA Market Share and BPS Analysis by Treatment, 2024 & 2034
Figure 142: MEA Market Y-o-Y Growth Projections by Treatment, 2024 to 2034
Figure 143: MEA Market Attractiveness Analysis by Treatment, 2024 to 2034
Figure 144: MEA Market Share and BPS Analysis by Disease, 2024 & 2034
Figure 145: MEA Market Y-o-Y Growth Projections by Disease, 2024 to 2034
Figure 146: MEA Market Attractiveness Analysis by Disease, 2024 to 2034
Figure 147: MEA Market Share and BPS Analysis by Cause, 2024 & 2034
Figure 148: MEA Market Y-o-Y Growth Projections by Cause, 2024 to 2034
Figure 149: MEA Market Attractiveness Analysis by Cause, 2024 to 2034
Figure 150: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 151: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 152: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the uveitis treatment market in 2024?
The global market for uveitis treatment is estimated at US$ 791 million in 2024.
What are the projections for the global market by 2034?
Worldwide revenue from uveitis treatment is projected to reach US$ 1.4 billion by 2034-end.
How fast is the market for uveitis treatment forecasted to expand?
The uveitis treatment market is projected to advance at a CAGR of 5.8%.
What are the projections for the market in East Asia?
The East Asia market is estimated at US$ 117 million in 2024 and is projected to increase at 7% CAGR thereafter.
Who are the leading players in the uveitis treatment industry?
Graybug Vision, Inc., TopiVert Pharma Ltd., Pfizer Inc., and Ophthotech Corporation are some of the leading companies in the market.
At what pace is the market projected to grow in South Korea?
The market in South Korea is projected to expand at a CAGR of 9.4% through 2034.
Which type of uveitis treatment is widely popular?
Worldwide demand for corticosteroids is projected to ascend at 6.4% through 2034.
Uveitis Treatment Market